Build status - In Progress

Analysis of lymphatic fluid from the thoracic duct of healthy subjects and patients with MS before and during Ofatumumab treatment

Recruiting
99 years or below
All
24 participants needed
1 Location

Brief description of study

The overall objectives of this study are to evaluate feasibility and safety of thoracic duct sampling, including "in-and-out" cannulation and "indwelling" catheterization in early MS and to compare cellular and signaling markers in thoracic duct lymph compared to measures in the blood, within and across populations of MS patients before and after ofatumumab and compared to healthy controls. The study is designed to evaluate the safety and feasibility of collection of lymphoid fluid via thoracic duct cannulation in healthy people and people with MS. Assess the impact of ofatumumab treatment in patients with MS on biological measures in the thoracic duct fluid and in the blood.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 08 Feb 2023. Study ID: 849114

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center